Quantcast

Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program

July 9, 2008

SUNNYVALE, Calif., July 9 /PRNewswire-FirstCall/ — Cepheid today announced the appointment of leading molecular epidemiologist and expert on Healthcare Associated Infections, Fred Tenover, Ph.D., as Senior Director of Scientific Affairs. Dr. Tenover will serve as a liaison with the Infection Control community and will lead Cepheid’s Healthcare Associated Infection (HAI) Consortium program.

“The objective of the Cepheid HAI Consortium is to establish global connections between hospital laboratories and leading academic laboratories in order to track evolving drug resistance patterns, virulence determinants, and the emergence of new strains associated with specific HAIs. The resulting information will be used in the design of rapid and definitive new tests for HAIs and for ensuring that Cepheid’s leadership position in this area is maintained and expanded,” said David H. Persing, M.D., Ph.D., Chief Medical and Technology Officer at Cepheid. “Dr. Tenover is a noted microbiologist and authority on HAI-associated organisms and as such, is uniquely qualified to head Cepheid’s HAI Consortium Program. I am extremely pleased to welcome such an accomplished scientist to our team and look forward to Fred’s contribution as we continue to expand and refine our menu of molecular tests in this important developing market.”

Dr. Tenover currently holds the position of Distinguished Consultant and Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention, Atlanta, GA. In addition, Dr. Tenover is Director, Centers for Disease Control and Prevention/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring, Atlanta, GA and is Adjunct Professor in the Department of Epidemiology, Emory University School of Public Health, Atlanta, GA.

“Finding effective treatment for the increasing number of multiple antibiotic resistant HAIs has become a serious challenge for physicians not only in U.S. hospitals but around the world,” said Dr. Tenover. “Providing physicians with the critical laboratory data they need to make decisions within a few hours instead of a few days will not only save lives but will help control the spread of infections in healthcare settings. I am delighted to have the opportunity to join forces with the distinguished team of scientists at Cepheid to confront the increasing burden of HAIs on human health.”

   Dr. Tenover is expected to join the Cepheid team in early October, 2008.    About Cepheid  

Cepheid , based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

This press release contains forward-looking statements that are not purely historical regarding Cepheid’s or its management’s intentions, beliefs, expectations and strategies for the future, including those relating to future product development. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company’s current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen development and manufacturing problems; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; the performance and market acceptance of new products; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; and underlying market conditions worldwide. Readers should also refer to the section entitled “Risk Factors” in Cepheid’s Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    CONTACTS:    For Media                   For Cepheid Investor    Inquiries:                  Inquiries:    Jared Tipton                Jacquie Ross    Cepheid Corporate           Cepheid Investor    Communications              Relations    408-400-8377                408-400-8329    jared.tipton@cepheid.com    jacquie.ross@cepheid.com  

Cepheid

CONTACT: media, Jared Tipton, Cepheid Corporate Communications,+1-408-400-8377, jared.tipton@cepheid.com, or investors, Jacquie Ross, CepheidInvestor Relations, +1-408-400-8329, jacquie.ross@cepheid.com, both ofCepheid

Web site: http://www.cepheid.com/




comments powered by Disqus